| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() MabThera Approved In Europe For Non-Hodgkin's Lymphoma SAN DIEGO, CA -- June 3, 1998 -- The European Commission has granted marketing authorisation to F. Hoffmann-LaRoche’s MabThera® (rituximab) for patients suffering from relapsed or chemoresistant follicular B-cell non-Hodgkin’s lymphoma in all European Union countries. Rituximab is co-promoted in the United States by IDEC Pharmaceuticals Corp. and Genentech under the tradename, Rituxan(TM) The first monoclonal antibody therapy for the treatment of patients suffering from non-Hodgkin's B-cell lymphoma, MabThera will be available initially to patients in the United Kingdom and Germany, with launch in other member states of the European Union to follow soon afterward. Rituximab was approved by the U.S. Food and Drug Administration on Nov. 26, 1997. The treatment is indicated for relapsed or refractory low grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma.
|